Market Environment - Nasdaq's IPO underpricing is influenced by macroeconomic conditions, monetary policy, and investor risk appetite, which directly affect the funding support for new listings [2] - The Nasdaq index, while focused on tech stocks, is significantly impacted by overall market trends, including economic downturns and geopolitical conflicts, leading to a higher likelihood of IPO failures during such periods [2] Company Fundamentals - Companies listed on Nasdaq are primarily growth-oriented, particularly in sectors like technology, biotech, and renewable energy, but investors demand high certainty in short-term profitability and long-term competitiveness [2] - Basic flaws in a company's fundamentals can easily trigger IPO underpricing, especially if there are significant slowdowns in revenue growth or widening losses [2] Valuation Dynamics - The core issue of IPO underpricing often lies in the conflict between high valuations in the primary market and rational pricing in the secondary market [2] - Companies that have inflated valuations due to prior funding rounds may face significant challenges in the public market if they do not adjust their expectations before the IPO [4] Issuance Mechanism - The IPO pricing mechanism, typically determined by investment banks through book building, can amplify the risk of underpricing if the pricing deviates from market realities [2] - The "anchor effect" from recent comparable company valuations may fail if there are sudden market changes, leading to mispriced IPOs [4] Long-term Perspective - IPO underpricing does not necessarily indicate a company's failure; some quality firms may rebound as market conditions improve or as their fundamentals become more apparent [3] - Companies need to demonstrate improvements in fundamentals, such as revenue growth and reduced losses, to recover from initial underpricing [4] Key Risks - Companies in competitive sectors without unique advantages may be viewed as highly replaceable, increasing the risk of underpricing [2] - Specific events, such as clinical trial failures for biotech firms or regulatory issues for tech companies, can severely impact investor confidence and lead to significant stock price drops [2]